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Abstract
Background: Trials of novel agents are required to improve the care of patients with rare diseases, but trial
feasibility may be uncertain due to concerns over insufficient patient numbers. We aimed to determine the size of
the pool of potential participants in England 2015–2017 for trials in the autoimmune blistering skin disease bullous
pemphigoid.
Methods: The size of the pool of potential participants was estimated using routinely collected healthcare data
from linked primary care (Clinical Practice Research Datalink; CPRD) and secondary care (Hospital Episode Statistics;
HES) databases. Thirteen consultant dermatologists were surveyed to determine the likelihood that a patient would
be eligible for a trial based on the presence of cautions or contra-indications to prednisolone use. These criteria
were applied to determine how they influenced the potential pool of participants.
Results: Extrapolated to the population of England, we would expect approximately 10,800 (point estimate 10,747;
95% CI 7191 to 17,239) new cases of bullous pemphigoid to be identified in a three-year period. For a future trial
involving oral prednisolone (standard care), the application of cautions to its use as exclusion criteria would result in
approximately 365 potential participants unlikely to be recruited, a further 5332 could be recruited with caution,
and 5104 in whom recruitment is still possible. 11–17% of potential participants may have pre-existing dementia
and require an alternative consent process.
Conclusions: Routinely collected electronic health records can be used to inform the feasibility of clinical trials in
rare diseases, such as whether recruitment is feasible nationally and how long recruitment might take to meet
recruitment targets. Future trials of bullous pemphigoid in England may use the data presented to inform trial
design, including eligibility criteria and consent processes for enrolling people with dementia.
Keywords: Bullous pemphigoid, Electronic health records, Clinical practice research Datalink, Oral prednisolone,
Hospital episode Statistics, Trial design, Rare disease
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Background
Bullous pemphigoid is a rare blistering skin disease that
predominantly affects older people [1]. Following a diag-
nosis of bullous pemphigoid, individuals affected are al-
most three times more likely to die than their peers [1].
Current treatment regimens are often based on oral
prednisolone, which has been the mainstay of treatment
for decades. Oral prednisolone is effective in treating
blisters, but may lead to the development or exacerba-
tion of potentially life-limiting diseases such as diabetes
mellitus and infections [2, 3]. Trials of novel agents are
required in order to improve patient management, [4]
however, the pool of potentially eligible patients in the
UK is currently unknown.
Routinely collected electronic health records (EHR)
can be used to inform trial feasibility and guide trial de-
velopment. Many rare diseases are in need of clinical tri-
als of new treatments, however, it is difficult to proceed
with trial planning and design without first knowing if
there are enough people to make such a trial feasible.
The present work focuses on bullous pemphigoid, but
the methodology used may be relevant to a multitude of
rare diseases.
Using EHR, we aimed to estimate the number of new
cases of bullous pemphigoid over a three-year period in
England and to determine how many of these patients
were affected by conditions that may exclude them from
participating in a trial assuming a control arm treated




This was a descriptive study, reported using RECORD
guidelines for the reporting of studies conducted using
observational routinely collected health data [5].
Data sources
Two linked data sources were utilised: primary care data
from the Clinical Practice Research Datalink (CPRD)
GOLD and secondary care data from the Hospital Epi-
sode Statistics (HES).
The CPRD GOLD is a longitudinal database that con-
tains the anonymised healthcare records for UK general
practices using the Vision software system. Within the
CPRD, clinical data from consultations, hospital dis-
charge letters, and specialist clinic letters are recorded
using Read codes [6, 7].
Linked data are available from HES admitted patient
care for approximately 75% of the English practices
within the CPRD, covering approximately 10 million
people. Within the HES admitted patient care, diagnoses
from each hospitalisation episode are recorded using the
International Classification of Diseases version 10 (ICD-
10) and procedures are recorded using the Office of
Population Censuses and Surveys Classification of Inter-
ventions and Procedures (OPCS version 4.6).
Study population
Adult men and women registered with the 410 HES-
linked general practices during the period of 1 January
2015 and 31 December 2017 formed the study popula-
tion for the examination of the incidence rate of bullous
pemphigoid. Only patients whose record was verified as
“acceptable” research quality were included. To ensure
higher validity of the included patient records, standard
data quality checks are conducted to identify and ex-
clude “unacceptable” patients with non-continuous fol-
low up (i.e., not permanently registered with the
practice) or poor data recording [7].
For the application of trial exclusion criteria, a subset
of the population above was used. Here it was limited to
those with an incident diagnosis of bullous pemphigoid
between 1 January 2015 and 31 December 2017. Inci-
dent diagnoses were those with a bullous pemphigoid
index date at least one year after their current registra-
tion date with their GP. The one-year lag period was im-
plemented in order to minimise the risk of prevalent
cases being identified as incident cases [8].
A diagnosis of bullous pemphigoid is generally made
in dermatology clinics, following clinical examination
and laboratory investigations, (e.g., skin biopsy for hist-
ology and direct immunofluorescence). The diagnosis is
subsequently communicated to primary care, where it is
usually entered in the CPRD using Read codes, or to the
person’s inpatient hospital records, where it is entered in
HES admitted patient care using ICD-10 codes. Patients
with a Read code for “bullous pemphigoid” (M145),
“pemphigoid “(M145.00), “pemphigoid not otherwise
specified” (M145z00) or an ICD-10 code for “bullous
pemphigoid” (L12.0) or “pemphigoid, unspecified”
(L12.9) were identified using a validated clinical-code
based algorithm [9].
Observation period
The three-year study included two observation periods:
one observation period for the calculation of the inci-
dence rate and one for the application of trial exclusion
criteria to the population of incident cases, described
below.
For the incidence calculation, the observation period
commenced on the latest of (i) 1 January 2015, (ii) 12
months after the date the patient registered with their
current practice, (iii) the date the patient’s practice was
declared up-to-standard (i.e., date assigned on comple-
tion of regular audits confirming data quality), or (iv)
the patient’s 18th birthday. The observation period ter-
minated on the earliest of (i) 31 December 2017, (ii) the
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date of death, (iii) the date the patient left the practice,
(iv) the practice’s last data collection date, or (v) the
most recent linkage date between the CPRD and HES.
When applying the trial exclusion criteria to incident
cases, only data prior to the bullous pemphigoid index
date were examined. Therefore the observation period
commenced on the practice’s up-to-standard date and
terminated on the index date for bullous pemphigoid.
Definitions of exclusion criteria
Contra-indications or cautions to oral prednisolone use
were identified from those listed in the British National
Formulary (BNF, 2020) [3]. A total of 2 contra-
indications and 19 cautions were identified. An add-
itional caution, malignancy (excluding basal cell carcin-
oma, BCC), was added to the list as it is an exclusion
criteria that has previously been implemented in clinical
trials of oral corticosteroid in bullous pemphigoid [10,
11]. Based on the guidance in the BNF and clinical
expertise, each contraindication was coupled to a speci-
fied timeframe of relevance, relative to the bullous pem-
phigoid index date (Table 1). For example, receiving a
varicella zoster vaccine was only a contra-indication to
oral prednisolone use if it occurred in the three months
preceding the bullous pemphigoid index date. Con-
versely, osteoporosis was considered a caution if it oc-
curred any time before the bullous pemphigoid date.
Using an online survey (Microsoft Office Forms), 13
consultant dermatologists experienced in managing bul-
lous pemphigoid graded whether they were “very likely”,
“somewhat likely”, or “unlikely” to exclude a person
from a trial involving oral prednisolone if they had a his-
tory of any of the 22 conditions within the specified time
frames. The dermatologists were all UK-based and iden-
tified based on their involvement with the British Asso-
ciation of Dermatologists guidelines for the management
of pemphigus vulgaris and bullous pemphigoid or the
Pemphigoid and Pemphigus Priority Setting Partnership.
Table 1 Conditions listed as cautions to the use of oral corticosteroids in the British National Formulary and the number
(proportion) of incident cases of bullous pemphigoid with a record for each caution within specified timelines. Presented alongside
the recruitment status associated with having that condition when considering a clinical trial involving 0.5 mg/kg oral prednisolone
Caution Timeline* N (%) of cases Recruitment status**
Total incident cases 237
Diabetes mellitus Any time before 55 (23.2%) Recruit with caution
Diverticulitis In 1 year before 0 Possible
Epilepsy Any time before 12 (5.1%) Possible
Glaucoma Any time before 16 (6.8%) Recruit with caution
Heart failure Any time before 43 (18.1%) Recruit with caution
Hypertension Any time before 159 (67.1%) Possible
Hypothyroidism Any time before 30 (12.7%) Possible
Intestinal anastomosis In 6 months before 1 (0.4%) Unlikely
Malignancy (excluding BCC) In 5 years before 23 (9.7%) Possible
Myasthenia gravis Any time before 1 (0.4%) Possible
Myocardial infarction In 6 months before 3 (1.3%) Recruit with caution
Myopathy Any time before 1 (0.4%) Recruit with caution
Ocular herpes simplex Any time before 1 (0.4%) Unlikely
Osteoporosis Any time before 38 (16.0%) Recruit with caution
Peptic ulcer In 1 year before 2 (0.8%) Recruit with caution
Septicaemia/sepsis In 3 months before 3 (1.3%) Unlikely
Severe mental illness In 10 years before 1 (0.4%) Recruit with caution
Systemic sclerosis Any time before 0 Possible
Venous thromboembolic disorders Any time before 19 (8.0%) Possible
Tuberculosis Any time before 3 (1.3%) Unlikely
Ulcerative colitis In 5 years before 2 (0.8%) Possible
Varicella zoster vaccine In 3 months before 4 (1.7%) Recruit with caution
* Timeline relative to bullous pemphigoid index date
** Recruitment status was determined by the category chosen by > 50% of the consultant dermatologists in the online survey: Possible (> 50% classed the caution
unlikely to lead to exclusion), recruit with caution (> 50% classed the caution very or somewhat likely to lead to exclusion, note that < 50% considered it very
likely), or unlikely (> 50% classed the caution as very likely to lead to exclusion)
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Responses were pooled and where there were discrepan-
cies, the caution was classified in accordance with the
category chosen by > 50% of dermatologists. This was
felt to be a reasonable cut-off for determining
consensus.
Code lists for exclusion criteria and dementia
Code lists were developed for the 22 cautions/contra-
indications considered potential exclusion criteria for
a trial involving oral prednisolone and for dementia.
Since bullous pemphigoid generally affects older
people, where the prevalence of dementia is increased,
[12] it was felt important to identify pre-existing de-
mentia, as well as prednisolone cautions, to provide
an indication of the proportion of patients with cap-
acity to consent.
Primary care and secondary care code lists were devel-
oped for each caution based on published Read and
ICD-10 lists, respectively. The code lists were primarily
drawn from the work of Kuan et al., [12] a study of 308
physical and mental health conditions, as this allowed a
consistent approach to be applied across all conditions,
and were modified and supplemented as required. For
example, only codes from the CALIBER “Thyroid dis-
ease” category that indicated decreased thyroid function
were used for hypothyroidism in the current work. Add-
itionally, the code lists for cautions coupled with a lim-
ited time frame (e.g., six months before bullous
pemphigoid) were manually reviewed and codes stating
“history of” or similar were excluded.
The code lists were supplemented with Read, ICD-10,
and OPCS codes generated through manual searching of
the data dictionaries. Finally, varicella zoster code lists
involving product and vaccination codes were drawn
from the work of Jain et al., [13]. Code lists were
reviewed in conjunction with a consultant dermatologist
(KEH) to ensure suitability and clinical relevance. Full
code lists are available in the Additional File 1.
Identification of exclusion criteria and dementia
The code lists were applied to the CPRD clinical, refer-
ral, test, therapy, and immunisation data and HES ad-
mitted patient care and OPCS data. For cautions with a
time frame of “any time before bullous pemphigoid”, all
codes prior to the bullous pemphigoid index date were
identified. For conditions with a limited time frame (e.g.,
in the “x months” before bullous pemphigoid) only
codes that occurred in the “x months” before bullous
pemphigoid, but at least 12 months after the patient’s
current registration date were examined. The time limit
of 12 months after the patient’s current registration date
was used to exclude potential historic events entered on
transfer to a new general practice.
Statistical analysis
The incidence rate of bullous pemphigoid was deter-
mined per 100,000 person-years using previously pub-
lished methods [1]. Age-specific incidence rates were
calculated for five-year age bands. These were applied to
the Office for National Statistics population estimate for
England [14] over the same time period to estimate the
total number of new cases that might be expected in
England.
Of the incident cases, the number and proportion with
a record for each of the cautions within the specified
time frame was determined. The proportion of patients
with conditions that were unlikely to allow recruitment
(recruitment unlikely group), that would be possible to
recruit with caution (recruit with caution group), and
that would be possible to recruit (recruitment possible
group) were determined. For each category, the propor-
tion with pre-existing dementia were determined. The
proportions were applied to the estimated number of
new cases in England 2015–2017.
Analyses were conducted with Stata 16 (2019; Stata-
Corp LLC, College Station, TX, USA).
Ethical approval
The present study was approved by the Independent Sci-
entific Advisory Committee for the CPRD (ISAC proto-
col no 18_224).
Results
Classification of recruitment status from survey
Of the 22 conditions considered to be contra-indications
or cautions, four were categorised as recruitment un-
likely (> 50% of dermatologists considered the disease
“very likely” to lead to exclusion), nine were recruit with
caution (> 50% of dermatologists considered the condi-
tion “very likely” or “somewhat likely” to lead to exclu-
sion; but < 50% of dermatologists considered the disease
“very likely”), and nine were recruitment possible (> 50%
of dermatologists considered the condition “unlikely” to
lead to exclusion).
Study population
Between 2015 and 2017, 237 incident cases of bullous
pemphigoid were identified in the CPRD and HES (Add-
itional File 2). The median age when the diagnosis of
bullous pemphigoid was first recorded was 78.7 years
(IQR 70.9 to 87.2). 134 (56.5%) of those affected were
women.
Incidence of bullous pemphigoid 2015–2017
The incidence of bullous pemphigoid was 8.4 (95%CI 7.4
to 9.5) per 100,000 person-years. The age-specific inci-
dence rates of bullous pemphigoid per age category are
available in the Additional File 3. Extrapolated to the
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population of England there would be an estimated 10,
800 (point estimate 10,747; 95% CI 7191 to 17,239) new
cases in England in a three-year period.
Cautions to oral prednisolone use
Of the incident cases, 44 (18.6%) had no recorded cau-
tions to the use of oral prednisolone. Conversely, 193
(81.4%) had a record for at least one caution to oral
prednisolone use. The commonest comorbidities consid-
ered cautions to the use of prednisolone and present at
the time the diagnosis of bullous pemphigoid was first
recorded were hypertension (67.1%), diabetes mellitus
(23.2%), heart failure (18.1%), and osteoporosis (16.0%)
(Table 1).
Classification of population by recruitment status
Across the incident cases, 112 (47.3%) patients were
considered possible to recruit (no caution or only cau-
tions unlikely to lead to exclusion), 117 (49.4%) could be
recruited with caution, and 8 (3.4%) would be unlikely to
be recruited to a trial of oral prednisolone. Extrapolated
to the population of England in 2015 to 2017, approxi-
mately 5104 would be possible to recruit and an add-
itional 5332 could be recruited with caution. However,
365 of incident cases would be unlikely to be recruited
due to cautions to the use of oral prednisolone. Of these,
911 (17.9%), 592 (11.1%), and 46 (12.5%), respectively,
may have pre-existing dementia (Table 2).
Discussion
We have described a novel use of EHRs, such as the
CPRD and HES, for the planning of clinical trials in rare
diseases. Although this approach has been on the agenda
for years, few publications incorporate this process in
trial planning. We have shown that data from EHRs may
be useful for determining whether conducting a trial for
a rare disease is feasible nationally, how many practices
might need to be approached, and how long recruitment
might take to meet recruitment targets. In addition,
linked EHR data can be used to determine how the pool
of eligible participants changes according to how trial
eligibility criteria are implemented.
We suggest the following considerations when using
EHR to plan the design and conduct of a trial. Firstly, it
should be possible to reliably identify the disease of
interest from the EHR available. Such validation work is
essential to ensure that the work captures patients with
the disease of interest. Secondly, consideration needs to
be paid to the comorbidities examined. We chose a
broad approach that might be useful for a variety of new
treatments, assuming the trials use oral prednisolone as
the comparator. In the future, researchers may choose to
use criteria that relate specifically to their research ques-
tion, treatments of interest, and sample size require-
ments. Finally, the benefits of conducting such a study
may be beneficial also during the conduct of a trial. The
characteristics of the population of potentially eligible
participants identified via EHR can be compared with
current recruitment patterns to determine the generalis-
ability of the study population and identify areas for im-
provement in the recruitment strategy.
For bullous pemphigoid, we have shown that pre-
existing comorbidities that are considered cautions to
oral prednisolone use are common at the time of diag-
nosis of bullous pemphigoid. As many as 81.4% of pa-
tients have at least one caution that may make them
ineligible for a clinical trial if all cautions were consid-
ered as exclusion criteria. This highlights that the bal-
ance between the safety of included patients and the
impact on the generalisability of trial results needs to be
considered. Finally, we have shown that trial planning
should consider patients with dementia, as about one in
six patients may have pre-existing dementia.
In keeping with the literature, cardiovascular comor-
bidities, and hypertension in particular, are common
amongst people with bullous pemphigoid. Indeed, co-
morbidities in general were common amongst the popu-
lation, which is reflective of the fact that bullous
pemphigoid most often affects older people [1]. Previous
work has shown that conditions such as hypertension,
malignancies, diverticular disease, heart failure, and
mental illnesses are common amongst the older popula-
tion that is also most susceptible to bullous pemphigoid.
However, not all comorbidities make a patient ineligible.
In a recent clinical trial involving oral prednisolone in
patients with bullous pemphigoid, approximately 9% of
individuals assessed for eligibility were excluded on the
grounds of “substantial comorbidities”. This significant
proportion suggests that in practice, clinicians assessing
patients for eligibility to a clinical trial may choose to ex-
clude not only the 3.4% we deemed ineligible, but also a
proportion of those we considered could be recruited
with caution.
A limitation of our work is the inability to determine
the severity of either the bullous pemphigoid or the cau-
tion, which are vital for clinical decision-making regard-
ing trial eligibility. Furthermore, we have not been able
to ascertain whether or not the cautions identified from
Table 2 Number (proportion) of the incident cases of bullous
pemphigoid with and without pre-existing dementia according
to their recruitment status
Recruitment status N With dementia Without dementia
All patients 237 34 (14.4%) 203 (85.7%)
Recruitment possible 112 20 (17.9%) 92 (82.1%)
Recruit with caution 117 13 (11.1%) 104 (88.9%)
Recruitment unlikely 8 1 (12.5%) 7 (87.5%)
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the CPRD and HES relate to therapy. It is possible that
oral prednisolone therapy was commenced in specialist
dermatology clinics prior to the recording of bullous
pemphigoid in the CPRD or HES and a small proportion
of the cautions observed, such as diabetes and osteopor-
osis, may be a consequence of the initial therapy. Add-
itionally, although we used both primary (CPRD) and
secondary care (HES) records to identify comorbidities,
the true number may be underestimated (resulting in a
misclassification bias) if patients have not sought med-
ical treatment for their condition or if the information
has not been recorded. However, we believe this number
is likely to be small and largely limited to conditions
with minor symptoms. The 13 consultant dermatologists
whose views shaped the classification of cautions were
chosen based on their experience in the area, but may
not be representative of all dermatologists that may be
involved in trial recruitment in the UK. Also, the data
drawn were from England and may not be representative
of other populations. Finally, our findings are based on a
relatively small number of patients identified in the
CPRD and HES over the most recent three-year period
for which the data were available. Expanding the obser-
vation period would have increased the numbers, but
was felt to reduce the applicability of findings to future
trials as disease recording and patient characteristics
may have changed over time.
Conclusions
In conclusion, we have used EHR to guide the design
and implementation of a clinical trial in bullous pem-
phigoid. We have provided an estimation of the number
of people that may be available to recruit to a trial in-
volving oral prednisolone. Researchers may use our find-
ings to determine the feasibility of conducting a clinical
trial of bullous pemphigoid in England based on their
specific sample size parameters. We suggest, however,
that recruitment is likely to be challenging and eligibility
criteria should be broad to ensure generalisable results.
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